{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T03:23:28Z","timestamp":1767842608352,"version":"3.49.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T00:00:00Z","timestamp":1586476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T00:00:00Z","timestamp":1586476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s40257-020-00514-2","type":"journal-article","created":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T18:02:26Z","timestamp":1586541746000},"page":"307-311","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Managing Cutaneous Immune-Mediated Diseases During the\u00a0COVID-19 Pandemic"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-0870","authenticated-orcid":false,"given":"Tiago","family":"Torres","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6083-0952","authenticated-orcid":false,"given":"Luis","family":"Puig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,10]]},"reference":[{"key":"514_CR1","unstructured":"European Centre for Disease Prevention and Control. Rapid risk assessment: coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the EU\/EEA and the UK\u2014seventh update. 2020. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/rapid-risk-assessment-coronavirus-disease-2019-covid-19-pandemic. Accessed 1 Apr 2020."},{"key":"514_CR2","unstructured":"World Health Organization. Coronavirus disease (COVID-19) pandemic. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019. Accessed 1 Apr 2020."},{"key":"514_CR3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet. 2020;395:497\u2013506. https:\/\/doi.org\/10.1016\/S0140-6736(20)30183-5.","journal-title":"China Lancet"},{"key":"514_CR4","unstructured":"Cascella M, Rajnik M, Cuomo A, et al. Features, evaluation and treatment coronavirus (COVID-19). StatPearls. Treasure Island (FL): StatPearls Publishing. 2020. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554776\/. Accessed 1 Apr 2020."},{"key":"514_CR5","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1080\/22221751.2020.1736644","volume":"9","author":"S-Y Fung","year":"2020","unstructured":"Fung S-Y, Yuen K-S, Ye Z-W, et al. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses. Emerg Microbes Infect. 2020;9:558\u201370. https:\/\/doi.org\/10.1080\/22221751.2020.1736644.","journal-title":"Emerg Microbes Infect"},{"key":"514_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12932\/AP-200220-0772","volume":"38","author":"E Prompetchara","year":"2020","unstructured":"Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38:1\u20139. https:\/\/doi.org\/10.12932\/AP-200220-0772.","journal-title":"Asian Pac J Allergy Immunol"},{"key":"514_CR7","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033\u20134. https:\/\/doi.org\/10.1016\/S0140-6736(20)30628-0.","journal-title":"Lancet"},{"key":"514_CR8","doi-asserted-by":"publisher","DOI":"10.1172\/JCI137647","author":"SF Pedersen","year":"2020","unstructured":"Pedersen SF, Ho Y-C. SARS-CoV-2: a storm is raging. J Clin Invest. 2020. https:\/\/doi.org\/10.1172\/JCI137647.","journal-title":"J Clin Invest."},{"key":"514_CR9","doi-asserted-by":"publisher","DOI":"10.1172\/JCI137244","author":"G Chen","year":"2020","unstructured":"Chen G, Wu D, Guo W, et al. Clinical and immunologic features in severe and moderate coronavirus disease 2019. J Clin Invest. 2020. https:\/\/doi.org\/10.1172\/JCI137244.","journal-title":"J Clin Invest."},{"key":"514_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa248","author":"C Qin","year":"2020","unstructured":"Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan. China. Clin Infect Dis. 2020. https:\/\/doi.org\/10.1093\/cid\/ciaa248.","journal-title":"China. Clin Infect Dis."},{"key":"514_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16387","author":"S Recalcati","year":"2020","unstructured":"Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020. https:\/\/doi.org\/10.1111\/jdv.16387.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"514_CR12","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00483-20","author":"H Li","year":"2020","unstructured":"Li H, Zhou Y, Zhang M, et al. Updated approaches against SARS-CoV-2. Antimicrob Agents Chemother. 2020. https:\/\/doi.org\/10.1128\/AAC.00483-20.","journal-title":"Antimicrob Agents Chemother."},{"key":"514_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa237","author":"X Yao","year":"2020","unstructured":"Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020. https:\/\/doi.org\/10.1093\/cid\/ciaa237.","journal-title":"Clin Infect Dis."},{"key":"514_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa114","author":"D Zhou","year":"2020","unstructured":"Zhou D, Dai S-M, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. 2020. https:\/\/doi.org\/10.1093\/jac\/dkaa114.","journal-title":"J Antimicrob Chemother."},{"key":"514_CR15","doi-asserted-by":"publisher","DOI":"10.7326\/M20-1223","author":"AHJ Kim","year":"2020","unstructured":"Kim AHJ, Sparks JA, Liew JW, et al. A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19. Ann Intern Med. 2020. https:\/\/doi.org\/10.7326\/M20-1223.","journal-title":"Ann Intern Med"},{"issue":"214","key":"514_CR16","doi-asserted-by":"publisher","first-page":"108393","DOI":"10.1016\/j.clim.2020.108393","volume":"25","author":"W Zhang","year":"2020","unstructured":"Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the experience of clinical immunologists from China. Clin Immunol. 2020;25(214):108393. https:\/\/doi.org\/10.1016\/j.clim.2020.108393.","journal-title":"Clin Immunol"},{"issue":"6","key":"514_CR17","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.autrev.2018.12.009","volume":"18","author":"P Sarzi-Puttini","year":"2019","unstructured":"Sarzi-Puttini P, Ceribelli A, Marotto D, et al. Systemic rheumatic diseases: from biological agents to small molecules. Autoimmun Rev. 2019;18(6):583\u201392. https:\/\/doi.org\/10.1016\/j.autrev.2018.12.009.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"514_CR18","doi-asserted-by":"crossref","first-page":"175","DOI":"10.55563\/clinexprheumatol\/r3k9l6","volume":"38","author":"F Ferro","year":"2020","unstructured":"Ferro F, Elefante E, Baldini C, et al. COVID-19: the new challenge for rheumatologists. Clin Exp Rheumatol. 2020;38(2):175\u201380.","journal-title":"Clin Exp Rheumatol."},{"key":"514_CR19","unstructured":"American Academy of Dermatology Association. Managing your practice through the COVID-19 outbreak. https:\/\/www.aad.org\/member\/practice\/managing\/coronavirus. Accessed 1 Apr 2020."},{"key":"514_CR20","unstructured":"International Psoriasis Council. Statement on the coronavirus (COVID-19) outbreak. https:\/\/www.psoriasiscouncil.org\/blog\/Statement-on-COVID-19-and-Psoriasis.htm. Accessed 1 Apr 2020."},{"key":"514_CR21","unstructured":"AEDV. Comunicado del Grupo de Psoriasis de la AEDV sobre la pandemia por COVID-19. Academia Espa\u00f1ola de Dermatolog\u00eda y Venereolog\u00eda. 2020. https:\/\/aedv.es\/comunicado-del-grupo-de-psoriasis-de-la-aedv-sobre-la-pandemia-por-covid-19\/. Accessed 1 Apr 2020."},{"key":"514_CR22","unstructured":"EULAR. EULAR guidance for patients COVID-19 outbreak. https:\/\/www.eular.org\/eular_guidance_for_patients_covid19_outbreak.cfm. Accessed 1 Apr 2020."},{"key":"514_CR23","unstructured":"IOIBD. IOIBD update on COVID19 for patients with Crohn\u2019s disease and ulcerative colitis. https:\/\/www.ioibd.org\/ioibd-update-on-covid19-for-patients-with-crohns-disease-and-ulcerative-colitis\/. Accessed 1 Apr 2020."},{"key":"514_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09546634.2020.1742438","volume":"19","author":"AM Bashyam","year":"2020","unstructured":"Bashyam AM, Feldman SR. Should patients stop their biologic treatment during the COVID-19 pandemic. J Dermatolog Treat. 2020;19:1\u20132. https:\/\/doi.org\/10.1080\/09546634.2020.1742438.","journal-title":"J Dermatolog Treat"},{"key":"514_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.031","author":"M Lebwohl","year":"2020","unstructured":"Lebwohl M, Rivera-Oyola R, Murrell DF. Should biologics for psoriasis be interrupted in the era of COVID-19? J Am Acad Dermatol. 2020. https:\/\/doi.org\/10.1016\/j.jaad.2020.03.031.","journal-title":"J Am Acad Dermatol."},{"key":"514_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.046","author":"KN Price","year":"2020","unstructured":"Price KN, Frew JW, Hsiao JL, et al. COVID-19 and immunomodulator\/immunosuppressant use in dermatology. J Am Acad Dermatol. 2020. https:\/\/doi.org\/10.1016\/j.jaad.2020.03.046.","journal-title":"J Am Acad Dermatol."},{"key":"514_CR27","doi-asserted-by":"publisher","first-page":"e13298","DOI":"10.1111\/dth.13298","volume":"11","author":"C Conforti","year":"2020","unstructured":"Conforti C, Giuffrida R, Dianzani C, et al. COVID-19 and psoriasis: is it time to limit treatment with immunosuppressants? A call for action. Dermatol Ther. 2020;11:e13298. https:\/\/doi.org\/10.1111\/dth.13298.","journal-title":"Dermatol Ther"},{"key":"514_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.056","author":"P Shah","year":"2020","unstructured":"Shah P, Zampella JG. Use of systemic immunomodulatory therapies during the coronavirus disease 2019 (COVID-19) pandemic. J Am Acad Dermatol. 2020. https:\/\/doi.org\/10.1016\/j.jaad.2020.03.056.","journal-title":"J Am Acad Dermatol."},{"key":"514_CR29","doi-asserted-by":"publisher","first-page":"102523","DOI":"10.1016\/j.autrev.2020.102523","volume":"20","author":"EG Favalli","year":"2020","unstructured":"Favalli EG, Ingegnoli F, De Lucia O, et al. COVID-19 infection and rheumatoid arthritis: faraway, so close! Autoimmun Rev. 2020;20:102523. https:\/\/doi.org\/10.1016\/j.autrev.2020.102523.","journal-title":"Autoimmun Rev"},{"issue":"10223","key":"514_CR30","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S0140-6736(20)30317-2","volume":"395","author":"CD Russell","year":"2020","unstructured":"Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473\u20135. https:\/\/doi.org\/10.1016\/S0140-6736(20)30317-2.","journal-title":"Lancet"},{"key":"514_CR31","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/QCO.0b013e328355660b","volume":"25","author":"A Kaltsas","year":"2012","unstructured":"Kaltsas A, Sepkowitz K. Community acquired respiratory and gastrointestinal viral infections: challenges in the immunocompromised host. Curr Opin Infect Dis. 2012;25:423\u201330. https:\/\/doi.org\/10.1097\/QCO.0b013e328355660b.","journal-title":"Curr Opin Infect Dis"},{"key":"514_CR32","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/S1473-3099(18)30127-0","volume":"18","author":"DS Hui","year":"2018","unstructured":"Hui DS, Azhar EI, Kim Y-J, et al. Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission. Lancet Infect Dis. 2018;18:e217\u2013e227227. https:\/\/doi.org\/10.1016\/S1473-3099(18)30127-0.","journal-title":"Lancet Infect Dis"},{"key":"514_CR33","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(20)30566-3.","journal-title":"Lancet"},{"key":"514_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/lt.25756","author":"L D\u2019Antiga","year":"2020","unstructured":"D\u2019Antiga L. Coronaviruses and immunosuppressed patients: the facts during the third epidemic. Liver Transpl. 2020. https:\/\/doi.org\/10.1002\/lt.25756.","journal-title":"Liver Transpl"},{"key":"514_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s12250-020-00207-4","author":"Y Fu","year":"2020","unstructured":"Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. Virol Sin. 2020. https:\/\/doi.org\/10.1007\/s12250-020-00207-4.","journal-title":"Virol Sin"},{"key":"514_CR36","unstructured":"Deng X, Yu X, Pei J. Regulation of interferon production as a potential strategy for COVID-19 treatment. https:\/\/www.researchgate.net\/publication\/339642124. Accessed 9 Apr 2020."},{"key":"514_CR37","doi-asserted-by":"publisher","first-page":"190109","DOI":"10.1098\/rsob.190109","volume":"9","author":"W-T Ma","year":"2019","unstructured":"Ma W-T, Yao X-T, Peng Q, et al. The protective and pathogenic roles of IL-17 in viral infections: friend or foe? Open Biol. 2019;9:190109. https:\/\/doi.org\/10.1098\/rsob.190109.","journal-title":"Open Biol"},{"key":"514_CR38","doi-asserted-by":"publisher","first-page":"e88716","DOI":"10.1371\/journal.pone.0088716","volume":"9","author":"E Faure","year":"2014","unstructured":"Faure E, Poissy J, Goffard A, et al. Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside? PLoS ONE. 2014;9:e88716. https:\/\/doi.org\/10.1371\/journal.pone.0088716.","journal-title":"PLoS ONE"},{"key":"514_CR39","doi-asserted-by":"publisher","first-page":"e00165","DOI":"10.1128\/mBio.00165-13","volume":"4","author":"L Josset","year":"2013","unstructured":"Josset L, Menachery VD, Gralinski LE, et al. Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus. mBio. 2013;4:e00165\u2013e1113. https:\/\/doi.org\/10.1128\/mBio.00165-13.","journal-title":"mBio."},{"issue":"4","key":"514_CR40","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","volume":"8","author":"Z Xu","year":"2020","unstructured":"Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420\u20132. https:\/\/doi.org\/10.1016\/S2213-2600(20)30076-X.","journal-title":"Lancet Respir Med"},{"key":"514_CR41","doi-asserted-by":"publisher","unstructured":"Hawill B, Geraci J (2020) Repurposing dupilumab may treat advanced COVID-19 patients with severe acute respiratory syndrome by mitigating cytokine storm. https:\/\/doi.org\/10.31219\/osf.io\/hk7ep","DOI":"10.31219\/osf.io\/hk7ep"},{"key":"514_CR42","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","volume":"395","author":"P Richardson","year":"2020","unstructured":"Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395:e30\u2013e3131. https:\/\/doi.org\/10.1016\/S0140-6736(20)30304-4.","journal-title":"Lancet"},{"key":"514_CR43","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1172\/JCI98814","volume":"128","author":"GAM Sanchez","year":"2018","unstructured":"Sanchez GAM, Reinhardt A, Ramsey S, et al. JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018;128:3041\u201352. https:\/\/doi.org\/10.1172\/JCI98814.","journal-title":"J Clin Invest"},{"key":"514_CR44","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1164\/rccm.201712-2371ED","volume":"197","author":"DS Hui","year":"2018","unstructured":"Hui DS. Systemic corticosteroid therapy may delay viral clearance in patients with Middle East respiratory syndrome coronavirus infection. Am J Respir Crit Care Med. 2018;197:700\u20131. https:\/\/doi.org\/10.1164\/rccm.201712-2371ED.","journal-title":"Am J Respir Crit Care Med"},{"key":"514_CR45","doi-asserted-by":"crossref","unstructured":"World Health Organization. Clinical management of severe acute respiratory infection when COVID-19 is suspected. https:\/\/www.who.int\/publications-detail\/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. Accessed 1 Apr 2020.","DOI":"10.15557\/PiMR.2020.0003"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-020-00514-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-020-00514-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-020-00514-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T01:09:32Z","timestamp":1666314572000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-020-00514-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,10]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["514"],"URL":"https:\/\/doi.org\/10.1007\/s40257-020-00514-2","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,10]]},"assertion":[{"value":"10 April 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding has been received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Tiago Torres has received consultancy and\/or speaker\u2019s honoraria from and\/or participated in clinical trials sponsored by AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Janssen, Biocad, LEO Pharma, Eli Lilly, MSD, Novartis, Pfizer, Samsung-Bioepis, Sanofi-Genzyme, and Sandoz. Luis Puig has received consultancy and\/or speaker\u2019s honoraria from and\/or participated in clinical trials sponsored by AbbVie, Almirall, Amgen, Baxalta, Biogen, Boehringer Ingelheim, Celgene, Gebro, Janssen, LEO Pharma, Eli Lilly and Company, Merck-Serono, MSD, Mylan, Novartis, Pfizer, Regeneron, Roche, Sandoz, Samsung-Bioepis, Sanofi, and UCB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}